Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:SRPT News 2 October 2025 - 26 January 2026

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·····
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta shares rose about 5% in after-hours trading Friday after the company announced it will release three-year Phase 3 data for its Duchenne gene therapy, Elevidys, on Jan. 26. The update follows recent FDA restrictions and safety warnings after deaths in non-ambulatory patients. Investors are watching for data on durability and safety. Sarepta will hold a webcast Monday morning to present the results.
24 January 2026
·····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that — for a stock that’s already been tossed around by safety concerns and shifts in treatment protocols over the past year. The timing coincides with the J.P. Morgan Healthcare Conference, where investors usually demand clear guidance and early insights for the
12 January 2026
····
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is back in the spotlight on Tuesday, December 16, 2025—not because the story suddenly got simpler, but because it’s at the intersection of three things the market obsessively prices every day: regulatory risk, clinical evidence, and cash runway. SRPT shares traded around $22 in the U.S. session on Dec. 16, up roughly a couple percent in morning trading. StockAnalysis That price level is a reminder of how dramatically sentiment has reset in 2025: Sarepta’s market capitalization now sits in the low single-digit billions (roughly $2–$3B, depending on intraday moves). StockAnalysis+2Yahoo Finance+2 So what’s “current” as
16 December 2025
·····
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last month marketbeat.com (though still down >80% from early 2025 levels). Trading volume has been moderate (0.6 million on Oct 2 vs. ~5–9M in prior days) investing.com. Over five trading days it gained +14.6% marketbeat.com, reflecting renewed investor interest. By contrast, the stock had sunk to ~$10–12 in mid-2025 amid safety concerns. Year-to-date, SRPT’s performance is dismal: a –82% return in one year marketbeat.com,
2 October 2025
·····

Stock Market Today

Corning stock price hits record close — what’s driving GLW and the next big test

Corning stock price hits record close — what’s driving GLW and the next big test

7 February 2026
Corning shares jumped 8.3% to a record $122.16 Friday, gaining 11% over two sessions amid strong demand for AI infrastructure stocks. The move follows a $6 billion optical fiber deal with Meta and upgraded company forecasts. Shares traded as high as $122.56 and rose 0.6% after hours. COO Avery Nelson sold 1,894 shares for tax withholding, retaining 66,050.
PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

PepsiCo stock: €2.5 billion bond deal lands as investors size up the price-cut gamble

7 February 2026
PepsiCo priced €2.5 billion in euro notes across four maturities, with settlement set for Feb. 11, according to an SEC filing. The company plans to use proceeds for general corporate purposes, including repaying commercial paper. Shares closed at $170.49 Friday, up 1.8%. PepsiCo is also cutting U.S. snack prices by up to 15% after consumer pushback.
Go toTop